2012-09-18 08:04:57 - Fast Market Research recommends "Lymphoma - Pipeline Review, H2 2012" from Global Markets Direct, now available
Global Markets Direct's, 'Lymphoma - Pipeline Review, H2 2012', provides an overview of the Lymphoma therapeutic pipeline. This report provides information on the therapeutic development for Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lymphoma. 'Lymphoma - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Full Report Details at
* A snapshot of the global therapeutic scenario for Lymphoma.
* A review of the Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Lymphoma pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.
Reasons to buy
* Identify and understand important and diverse types of therapeutics under development for Lymphoma.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Lymphoma pipeline depth and focus of Lymphoma therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Lymphoma Therapeutic Products under Development, Key Players in Lymphoma Therapeutics, Lymphoma Pipeline Overview, Lymphoma Pipeline, Lymphoma Pipeline Assessment
Partial Table of Contents:
Table of Contents
Table of Contents
List of Tables
List of Figures
Global Markets Direct Report Coverage
An Overview of Pipeline Products for Lymphoma
Lymphoma Therapeutics under Development by Companies
Lymphoma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Mid Clinical Stage Products
Early Clinical Stage Products
Discovery and Pre-Clinical Stage Products
Lymphoma Therapeutics - Products under Development by Companies
Lymphoma Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Lymphoma Therapeutics Development
Bristol-Myers Squibb Company
Johnson & Johnson
F. Hoffmann-La Roche Ltd.
Kyowa Hakko Kirin Co., Ltd.
Eli Lilly and Company
Seattle Genetics, Inc.
Tekmira Pharmaceuticals Corp.
MMR Information Systems, Inc.
Gilead Sciences, Inc.
Daiichi Sankyo Company, Ltd
Merck & Co., Inc.
Emergent BioSolutions Inc.
Gamida Cell Ltd.
Takeda Pharmaceutical Company Limited
Reliance Life Sciences Pvt. Ltd.
Piramal Healthcare Limited
Bio-Path Holdings, Inc.
ZIOPHARM Oncology, Inc.
Millennium Pharmaceuticals, Inc.
Astellas Pharma Inc.
BioMarin Pharmaceutical Inc.
Chong Kun Dang Pharmaceutical
Eisai Co., Ltd.
Glenmark Pharmaceuticals Ltd.
OSI Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Limited
Cell Therapeutics, Inc.
Santaris Pharma A/S
Onyx Pharmaceuticals, Inc.
Access Pharmaceuticals, Inc.
Celldex Therapeutics, Inc.
AEterna Zentaris Inc.
Idera Pharmaceuticals, Inc.
Northwest Biotherapeutics, Inc.
Cleveland BioLabs, Inc.
Accentia Biopharmaceuticals, Inc.
Allos Therapeutics, Inc
Portola Pharmaceuticals, Inc.
Mundipharma International Limited
Senesco Technologies, Inc.
Progen Pharmaceuticals Limited
Green Cross Corporation
SymBio Pharmaceuticals Limited
Chroma Therapeutics Ltd.
Chipscreen Biosciences Ltd
Aquinox Pharmaceuticals Inc.
Aegera Therapeutics Inc.
Ascenta Therapeutics, Inc.
Cerulean Pharma, Inc.
Provenance Biopharmaceuticals Corp.
Arno Therapeutics, Inc.
Fresenius Biotech GmbH
Semafore Pharmaceuticals, Inc.
MSM Protein Technologies, Inc.
Jennerex Biotherapeutics, Inc.
Synageva BioPharma Corp.
Cornerstone Pharmaceuticals, Inc.
Omnitura Therapeutics Inc.
Yaupon Therapeutics, Inc.
Onconova Therapeutics, Inc
TcL Pharma SAS
Full Table of Contents is available at:
About Global Markets Direct
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at www.fastmr.com
or call us at 1.800.844.8156.